论文部分内容阅读
目的探讨6种肿瘤标志物联合检测在肺癌诊断中的价值。方法选取2010年2月至2012年2月肺癌患者、肺良性疾病患者各40例为甲组、乙组,选取40例同期体检正常患者作为丙组,采用电化学发光法对各组研究者血中甲胎蛋白(AFP)、癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCCAg)、糖链抗原125(CA125)、细胞角质蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)含量。结果甲组CEA、CA125、CYFRA21-1、NSE含量明显高于其他两组;3种标志物联合检测中CEA+CA125+CYFRA21-1敏感性明显高于其他联合检测方法,其次为CEA+CA125+SCCAg;两种标志物联合检测中,CEA+CA125敏感性高于其他联合检测。结论通过标志物联合检测能够提高肺癌诊断敏感性及准确性,从而为临床尽早治疗提供准确依据,提高治愈率。
Objective To investigate the value of combined detection of six tumor markers in the diagnosis of lung cancer. Methods From February 2010 to February 2012, 40 patients with lung cancer and 40 patients with benign lung disease were selected as Group A and Group B. 40 normal subjects were selected as Group C in the same period. Electrochemiluminescence AFP, CEA, SCCAg, CA125, CYFRA21-1, neuron-specific enolase Enzyme (NSE) content. Results The levels of CEA, CA125, CYFRA21-1 and NSE in group A were significantly higher than those in the other two groups. The sensitivity of CEA + CA125 + CYFRA21-1 in the combination of three markers was significantly higher than that of other combined detection methods, followed by CEA + CA125 + SCCAg; CEA + CA125 sensitivity was higher in the combined detection of the two markers than in other combined tests. Conclusion Combined detection of markers can improve the diagnostic sensitivity and accuracy of lung cancer, so as to provide an accurate basis for early clinical treatment and improve the cure rate.